Law ex­perts ar­gue that abor­tion drug with­draw­al would 'un­der­mine' the ap­proval process

More than a dozen food and drug law ex­perts ar­gued on Wednes­day that yank­ing the med­ica­tion abor­tion drug mifepri­s­tone from the mar­ket would “un­der­mine the drug ap­proval process far be­yond the con­text of mifepri­s­tone’s ap­proval.”

The com­ments are in re­sponse to a Texas law­suit chal­leng­ing the 2000 ap­proval of mifepri­s­tone, which is used in com­bi­na­tion with miso­pros­tol to end preg­nan­cies with­in the first 10 weeks. Nine­teen schol­ars from sev­er­al uni­ver­si­ties — in­clud­ing Har­vard and Stan­ford’s law schools — ar­gued in an am­i­cus brief that a pre­lim­i­nary or­der to with­draw mifepri­s­tone’s ap­proval would be “un­prece­dent­ed and in­ap­pro­pri­ate.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.